SCHEMBL21252608

SCHEMBL21252608

Bc1c(B)c(B)c(-c2c3ccccc3c(-c3ccc(-c4ccccc4)c4oc5ccccc5c34)c3ccccc23)c(B)c1B

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC14B O60729 2/20 0.46
▸ CDC14A Q9UNH5 2/20 0.46
▸ CYP19A1 P11511 2/20 0.40
▸ CYP17A1 P05093 1/20 0.40
▸ CYP11B1 P15538 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ MAPT P10636 3/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ CA1 P00915 3/20 0.34
▸ CA2 P00918 3/20 0.34
▸ ALOX5 P09917 2/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ GAA P10253 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20246957 0.92 CDC14B (0.45) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL24178542 0.87 ALOX5 (0.39) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL17917499 0.86 CDC14B (0.51) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL22854798 0.86 CDC14B (0.51) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL22707251 0.85 CDC14B (0.50) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL23027121 0.85 CDC14B (0.50) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL26774247 0.84 CDC14B (0.38) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL25159215 0.84 MAOB (0.40) CDC14BCDC14ACYP19A1CA1CA2
SCHEMBL26404171 0.84 CDC14B (0.49) CDC14BCDC14ACYP19A1CYP17A1CYP11B1
SCHEMBL18382847 0.84 CDC14B (0.49) CDC14BCDC14ACYP19A1CYP17A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240023359-A1 ORGANIC LIGHT-EMITTING DEVICE COMPRISING NOVEL ORGANIC COMPOUND IN EMISSION LAYER SFC CO., LTD. (KR) 2024-01-18 — — US disclosed
US-20230371376-A1 POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME SFC CO., LTD. (KR) 2023-11-16 — — US disclosed
EP-3309235-B1 ORGANIC LIGHT EMITTING ELEMENT HAVING HIGH EFFICIENCY SFC CO LTD (KR) 2023-10-18 — — EP disclosed
EP-3524660-B1 ORGANIC LIGHT-EMITTING DEVICE HAVING LONG LIFE, LOW VOLTAGE AND HIGH EFFICIENCY SFC CO LTD (KR) 2022-06-15 — — EP disclosed
EP-3524661-B1 ORGANIC LIGHT-EMITTING DEVICE HAVING LONG LIFE, LOW VOLTAGE AND HIGH EFFICIENCY SFC CO LTD (KR) 2022-06-01 — — EP disclosed
US-11133472-B1 Organic light-emitting diode having long lifespan, low voltage, and high efficiency property SFC CO., LTD. (KR) 2021-09-28 — — US disclosed
US-10998505-B2 Organic light emitting diode for high efficiency SFC CO., LTD. (KR) 2021-05-04 — — US disclosed
EP-3524660-A1 ORGANIC LIGHT-EMITTING DEVICE HAVING LONG LIFE, LOW VOLTAGE AND HIGH EFFICIENCY SFC Co., Ltd. (KR) 2019-08-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10998505-B2 Organic light emitting diode for high efficiency ALDH1A2, ALDH1A1, CYBA CDC14B 2225/4885CDC14A 2014/4885CYP19A1 211/4885
US-20230371376-A1 POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME PPOX, MAP1LC3A, VDAC2 CDC14B 2715/4885CDC14A 2656/4885CYP19A1 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback